Ivonescimab plus chemo for metastatic colorectal cancer without liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type called pMMR/MSS and must not have the BRAF V600E mutation or be MSI-high.
- You must have already had one type of chemotherapy (like FOLFOX or FOLFIRINOX) for your advanced cancer.
- Your cancer must have spread to other organs, but not to your liver. If you had liver metastases treated before and they are gone, that is okay.
- You should be generally active and able to take care of yourself (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You need adequate blood, kidney, and liver function as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
This trial is for people with advanced colorectal cancer that has stopped responding to first-line treatment. It tests a combination of chemotherapy, a targeted therapy, and an investigational drug to see if it can help slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.